Biological Psychiatry

• 

  Publication Venue For

  • Epigenome-wide Association Study of Attention-Deficit/Hyperactivity Disorder Symptoms in Adults..  86:599-607. 2019
  • Convergent Evidence for Predispositional Effects of Brain Gray Matter Volume on Alcohol Consumption. 2019
  • Early Correction of N-Methyl-D-Aspartate Receptor Function Improves Autistic-like Social Behaviors in Adult Shank2-/- Mice..  85:534-543. 2019
  • A Connectome-wide Functional Signature of Transdiagnostic Risk for Mental Illness..  84:452-459. 2018
  • Replication in Imaging Genetics: The Case of Threat-Related Amygdala Reactivity..  84:148-159. 2018
  • T184. Effects of Pregnenolone Administration on Emotion Regulation Neurocircuits in Trauma Brain Injury.  83:S199-S200. 2018
  • Amygdala Reward Reactivity Mediates the Association Between Preschool Stress Response and Depression Severity..  83:128-136. 2018
  • Imaging Genetics and Genomics in Psychiatry: A Critical Review of Progress and Potential..  82:165-175. 2017
  • A Common Polymorphism in a Williams Syndrome Gene Predicts Amygdala Reactivity and Extraversion in Healthy Adults..  81:203-210. 2017
  • Interactions Between Anandamide and Corticotropin-Releasing Factor Signaling Modulate Human Amygdala Function and Risk for Anxiety Disorders: An Imaging Genetics Strategy for Modeling Molecular Interactions..  80:356-362. 2016
  • Eye Tracking Reveals Abnormal Visual Preference for Geometric Images as an Early Biomarker of an Autism Spectrum Disorder Subtype Associated With Increased Symptom Severity..  79:657-666. 2016
  • Blunted Ventral Striatum Development in Adolescence Reflects Emotional Neglect and Predicts Depressive Symptoms..  78:598-605. 2015
  • Testosterone rapidly increases neural reactivity to threat in healthy men: a novel two-step pharmacological challenge paradigm..  76:324-331. 2014
  • An inflammatory pathway links atherosclerotic cardiovascular disease risk to neural activity evoked by the cognitive regulation of emotion..  75:738-745. 2014
  • Testosterone Rapidly Increases Neural Reactivity to Threat in Healthy Men: A Novel Two-Step Pharmacological Challenge Paradigm 2014
  • A thalamocorticostriatal dopamine network for psychostimulant-enhanced human cognitive flexibility..  74:99-105. 2013
  • Can food and addiction change the game?.  73:802-803. 2013
  • An Inflammatory Pathway Links Atherosclerotic Cardiovascular Disease Risk to Neural Activity Evoked by the Cognitive Regulation of Emotion 2013
  • Functional brain activation to emotionally valenced faces in school-aged children with a history of preschool-onset major depression..  72:1035-1042. 2012
  • Ventral striatum reactivity to reward and recent life stress interact to predict positive affect..  72:157-163. 2012
  • Adenylate cyclase 7 is implicated in the biology of depression and modulation of affective neural circuitry..  71:627-632. 2012
  • Blunted cortisol responses to stress signal social and behavioral problems among maltreated/bullied 12-year-old children..  70:1016-1023. 2011
  • The what, where, and when of catechol-O-methyltransferase..  70:214-215. 2011
  • Structural magnetic resonance imaging in bipolar disorder: an international collaborative mega-analysis of individual adult patient data..  69:326-335. 2011
  • Arguable assumptions, debatable conclusions..  67:e19-e20. 2010
  • Preferential amygdala reactivity to the negative assessment of neutral faces..  66:847-853. 2009
  • Genetic vulnerability to affective psychopathology in childhood: a combined voxel-based morphometry and functional magnetic resonance imaging study..  66:231-237. 2009
  • Divergent effects of genetic variation in endocannabinoid signaling on human threat- and reward-related brain function..  66:9-16. 2009
  • Preclinical atherosclerosis covaries with individual differences in reactivity and functional connectivity of the amygdala..  65:943-950. 2009
  • Abnormalities in Inflammatory Lipid Levels in First Episode Schizophrenic Patients are Modulated by Risperidone.  65:170S-170S. 2009
  • Focality of Neural Stimulation with Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) in Humans and Non-Human Primates.  65:219S-220S. 2009
  • Homeostatic Imbalance of Purine Catabolism in First-Episode Neuroleptic-Naive Patients with Schizophrenia.  65:65S-65S. 2009
  • Metabolomics: A Global Biochemical Approach to the Study of Neuropsychiatric Disorders.  65:79S-79S. 2009
  • Individual differences in typical reappraisal use predict amygdala and prefrontal responses..  65:367-373. 2009
  • Interleukin-6 covaries inversely with hippocampal grey matter volume in middle-aged adults..  64:484-490. 2008
  • Classification of white matter lesions on magnetic resonance imaging in elderly persons..  64:273-280. 2008
  • Serotonin transporter (5-HTTLPR) genotype and amygdala activation: a meta-analysis..  63:852-857. 2008
  • Dopaminergic role in cannabis-induced psychosis? Genetic and imaging evidence.  63:153S-153S. 2008
  • A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder..  62:1149-1154. 2007
  • Advances in the pharmacotherapy of attention-deficit/hyperactivity disorder..  62:951-953. 2007
  • Revisiting the backward masking deficit in schizophrenia: individual differences in performance and modeling with transcranial magnetic stimulation..  62:793-799. 2007
  • Regarding "The Munich vulnerability study on affective disorders: premorbid polysomnographic profile of affected high-risk probands"..  62:703. 2007
  • Resting state cortical connectivity reflected in EEG coherence in individuals with autism..  62:270-273. 2007
  • Risperidone and cognitive function in children with disruptive behavior disorders..  62:226-234. 2007
  • The use of prazosin for the treatment of trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder..  61:925-927. 2007
  • NCAM1 and neurocognition in schizophrenia..  61:902-910. 2007
  • Serotonin transporter genotype (5-HTTLPR): effects of neutral and undefined conditions on amygdala activation..  61:1011-1014. 2007
  • Errata.  61:826-826. 2007
  • Early pharmacological treatment of autism: a rationale for developmental treatment..  61:521-537. 2007
  • Rate of head growth decelerates and symptoms worsen in the second year of life in autism..  61:458-464. 2007
  • Cognitive behavioral treatment for young children with obsessive-compulsive disorder..  61:337-343. 2007
  • Tics moderate treatment outcome with sertraline but not cognitive-behavior therapy in pediatric obsessive-compulsive disorder..  61:344-347. 2007
  • Facial expressions of emotion reveal neuroendocrine and cardiovascular stress responses..  61:253-260. 2007
  • Local knockdown of genes in the brain using small interfering RNA: a phenotypic comparison with knockout animals..  61:65-69. 2007
  • The Biological Bases of Nicotine and Alcohol Co-Addiction.  61:1-3. 2007
  • Dorsolateral prefrontal cortex and anterior cingulate cortex white matter alterations in late-life depression..  60:1356-1363. 2006
  • Psychiatric disease in the twenty-first century: The case for subcortical ischemic depression..  60:1299-1303. 2006
  • The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease..  60:1287-1294. 2006
  • Prefrontal-hippocampal coupling during memory processing is modulated by COMT val158met genotype..  60:1250-1258. 2006
  • Mood alters amygdala activation to sad distractors during an attentional task..  60:1139-1146. 2006
  • Human choline transporter gene variation is associated with corticolimbic reactivity and autonomic-cholinergic function..  60:1155-1162. 2006
  • Prevalence, clinical correlates, and longitudinal course of severe mood dysregulation in children..  60:991-997. 2006
  • Cerebellar volumes in pediatric maltreatment-related posttraumatic stress disorder..  60:697-703. 2006
  • Cognitive function in late life depression: relationships to depression severity, cerebrovascular risk factors and processing speed..  60:58-65. 2006
  • Attrition in Randomized Controlled Clinical Trials: Methodological Issues in Psychopharmacology.  59:1001-1005. 2006
  • Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder..  59:1052-1060. 2006
  • Advancing the boundaries of molecular imaging..  59:881-882. 2006
  • Imaging genetics: perspectives from studies of genetically driven variation in serotonin function and corticolimbic affective processing..  59:888-897. 2006
  • Segmented hippocampal volume in children and adolescents with posttraumatic stress disorder..  59:523-529. 2006
  • Evidence for impaired cortical inhibition in patients with unipolar major depression..  59:395-400. 2006
  • Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis..  59:97-105. 2006
  • Facial expressions of emotion reveal neuroendocrine and cardiovascular stress responses..  58:743-750. 2005
  • Aging-related diagnostic variations: need for diagnostic criteria appropriate for elderly psychiatric patients..  58:265-271. 2005
  • Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients..  58:297-306. 2005
  • Mood disorders in the medically ill: scientific review and recommendations..  58:175-189. 2005
  • Through the looking glass: risk perception..  57:1477-1478. 2005
  • Variation of human amygdala response during threatening stimuli as a function of 5'HTTLPR genotype and personality style..  57:1517-1525. 2005
  • Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction..  57:1117-1127. 2005
  • Defining a cognitive function decrement in schizophrenia..  57:688-691. 2005
  • Perfusion abnormalities and decision making in cocaine dependence..  56:527-530. 2004
  • Prevention of postpartum episodes in women with bipolar disorder..  56:592-596. 2004
  • Approaching a consensus cognitive battery for clinical trials in schizophrenia: the NIMH-MATRICS conference to select cognitive domains and test criteria..  56:301-307. 2004
  • Chronic very low dose naltrexone administration attenuates opioid withdrawal expression..  56:261-268. 2004
  • Pituitary volumes in pediatric maltreatment-related posttraumatic stress disorder..  55:752-758. 2004
  • Testosterone, antisocial behavior, and social dominance in boys: pubertal development and biosocial interaction..  55:546-552. 2004
  • Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression..  55:390-397. 2004
  • Diffusion tensor imaging: background, potential, and utility in psychiatric research..  55:201-207. 2004
  • A magnetic resonance spectroscopic imaging study of adult nonhuman primates exposed to early-life stressors..  54:727-735. 2003
  • Apolipoprotein E genotype and subcortical vascular lesions in older depressed patients and control subjects..  54:674-681. 2003
  • Focal and lateralized subcortical abnormalities in unipolar major depressive disorder: an automated multivoxel proton magnetic resonance spectroscopy study..  54:744-750. 2003
  • Subcortical lesion severity and orbitofrontal cortex volume in geriatric depression..  54:529-533. 2003
  • Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial..  54:444-452. 2003
  • Depression and cardiovascular disease: mechanisms of interaction..  54:248-261. 2003
  • Persistent pain and depression: a biopsychosocial perspective..  54:399-409. 2003
  • Neocortical modulation of the amygdala response to fearful stimuli..  53:494-501. 2003
  • Physiologic impairment of olfactory stimulus processing in schizophrenia..  53:403-411. 2003
  • Effectiveness of chromium in atypical depression: a placebo-controlled trial..  53:261-264. 2003
  • Maternal smoking during pregnancy and risk to boys' conduct disturbance: an examination of the causal hypothesis..  53:130-135. 2003
  • Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial..  53:188-191. 2003
  • Smaller orbital frontal cortex volumes associated with functional disability in depressed elders..  53:144-149. 2003
  • Brain structures in pediatric maltreatment-related posttraumatic stress disorder: a sociodemographically matched study..  52:1066-1078. 2002
  • Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia..  52:701-707. 2002
  • Comorbidity of depression with other medical diseases in the elderly..  52:559-588. 2002
  • Comorbidity of late life depression: an opportunity for research on mechanisms and treatment..  52:543-558. 2002
  • Development and natural history of mood disorders..  52:529-542. 2002
  • An open label trial of C-1073 (mifepristone) for psychotic major depression..  52:386-392. 2002
  • Biological risk factors in late life depression..  52:185-192. 2002
  • An application of the revised CONSORT standards to FDA summary reports of recently approved antidepressants and antipsychotics..  52:62-67. 2002
  • Verapamil treatment for women with bipolar disorder..  51:745-752. 2002
  • Superior temporal gyrus volumes in maltreated children and adolescents with PTSD..  51:544-552. 2002
  • Superior temporal gyrus volumes in pediatric generalized anxiety disorder..  51:553-562. 2002
  • APOE genotype and hippocampal volume change in geriatric depression..  51:426-429. 2002
  • Vagus nerve stimulation (VNS) for major depressive episodes: one year outcomes..  51:280-287. 2002
  • Sensitization to the cardiovascular but not subject-rated effects of oral cocaine in humans..  51:143-150. 2002
  • Cytokine effects on cortical neuron MAP-2 immunoreactivity: implications for schizophrenia..  50:743-749. 2001
  • Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity..  50:644-646. 2001
  • Performance feedback deficit in geriatric depression..  50:358-363. 2001
  • A pilot longitudinal study of hippocampal volumes in pediatric maltreatment-related posttraumatic stress disorder..  50:305-309. 2001
  • MRI correlates of suicide attempt history in unipolar depression..  50:266-270. 2001
  • Evidence of white matter tract disruption in MRI hyperintensities..  50:179-183. 2001
  • Specific psychotherapies for childhood and adolescent depression..  49:1091-1100. 2001
  • Right amygdala volume in adolescent and young adult offspring from families at high risk for developing alcoholism..  49:894-905. 2001
  • Medial orbital frontal lesions in late-onset depression..  49:803-806. 2001
  • Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials..  49:460-463. 2001
  • Elevated motor threshold in drug-free, cocaine-dependent patients assessed with transcranial magnetic stimulation..  49:369-373. 2001
  • Cognitive effects of nicotine..  49:258-267. 2001
  • Reduction of orbital frontal cortex volume in geriatric depression..  48:971-975. 2000
  • Hippocampal volume in geriatric depression..  48:301-309. 2000
  • Inhibitory control in children with attention-deficit/hyperactivity disorder: event-related potentials identify the processing component and timing of an impaired right-frontal response-inhibition mechanism..  48:238-246. 2000
  • A pilot study of amygdala volumes in pediatric generalized anxiety disorder..  48:51-57. 2000
  • Olanzapine increases allopregnanolone in the rat cerebral cortex..  47:1000-1004. 2000
  • Efficient trial designs to reduce placebo requirements..  47:724-726. 2000
  • 34. Serotonin transporter genotypes, CSF 5HIAA, and cardiovascular reactivity to stress.  47:S10-S10. 2000
  • 410. Interactive effects in the anterior cingulate of sadness and selective attention: a PET study.  47:S125-S126. 2000
  • Dexamethasone metabolism in dexamethasone suppression test suppressors and nonsuppressors..  47:677-680. 2000
  • Vagus nerve stimulation: a new tool for brain research and therapy..  47:287-295. 2000
  • Genetic approaches to studying norepinephrine function: knockout of the mouse norepinephrine transporter gene..  46:1124-1130. 1999
  • Functional hyperdopaminergia in dopamine transporter knock-out mice..  46:303-311. 1999
  • Smoking and therapeutic response to clozapine in patients with schizophrenia..  46:125-129. 1999
  • A.E. Bennett Research Award. Developmental traumatology. Part II: Brain development..  45:1271-1284. 1999
  • A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder..  45:1226-1229. 1999
  • A.E. Bennett Research Award. Developmental traumatology. Part I: Biological stress systems..  45:1259-1270. 1999
  • Hyperintense lesions on magnetic resonance images in bipolar disorder..  45:965-971. 1999
  • Normal CSF oxytocin and NPY levels in OCD..  45:931-933. 1999
  • Prolactin response to electroconvulsive therapy..  45:378-381. 1999
  • Generalized anxiety disorder: neurobiological and pharmacotherapeutic perspectives..  44:1286-1294. 1998
  • Effects of electroconvulsive therapy on plasma vasopressin and oxytocin..  44:610-616. 1998
  • Magnetic resonance imaging correlates of depression in early- and late-onset Alzheimer's disease..  44:592-599. 1998
  • Ventricular enlargement in poor-outcome schizophrenia..  43:783-793. 1998
  • Plasma dexamethasone concentration and cortisol response during manic episodes..  43:747-754. 1998
  • Structural neuroimaging and mood disorders: recent findings, implications for classification, and future directions..  43:705-712. 1998
  • 196. Onset of alzheimer's disease in susceptible subjects: Influence of APOE.  43:S58-S58. 1998
  • Effects of electroconvulsive therapy in adolescents with severe endogenous depression resistant to pharmacotherapy..  43:335-338. 1998
  • Whole blood serotonin relates to violence in an epidemiological study..  43:446-457. 1998
  • Tryptophan depletion in recently manic patients treated with lithium..  43:230-232. 1998
  • Prolactin response to electroconvulsive therapy: effects of electrode placement and stimulus dosage..  43:146-155. 1998
  • A repeat proton magnetic resonance spectroscopy study in social phobia..  42:419-424. 1997
  • Clozapine-induced electroencephalogram changes as a function of clozapine serum levels..  42:132-137. 1997
  • Effect of nitrous oxide on cerebral blood velocity while reclining and standing..  41:979-984. 1997
  • A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease..  41:851-856. 1997
  • Cerebral vasodilation and vasoconstriction associated with acute anxiety..  41:782-795. 1997
  • EEG correlates of the response to ECT.  41:189-189. 1997
  • Response.  41:912-913. 1997
  • Serotonin transporter expression in rat brain regions and blood platelets: aging and glucocorticoid effects..  41:172-183. 1997
  • A study of the potential confounding effects of diet, caffeine, nicotine and lorazepam on the stability of plasma and urinary homovanillic acid levels in patients with schizophrenia..  40:1218-1221. 1996
  • Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale..  40:755-760. 1996
  • Acute changes in cranial blood flow after cocaine hydrochloride..  40:609-616. 1996
  • Do glucocorticoids contribute to the abnormalities in serotonin transporter expression and function seen in depression? An animal model..  40:576-584. 1996
  • Apolipoprotein E-epsilon 4 frequency in geriatric depression..  40:69-71. 1996
  • Impact of neuroleptic medications on continuous performance test measures in schizophrenia..  39:902-905. 1996
  • Cognitive impairment in elderly depressed individuals with APOE epsilon 4.  39:539-539. 1996
  • Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia..  38:696-698. 1995
  • Seizure threshold in electroconvulsive therapy (ECT) II. The anticonvulsant effect of ECT..  37:777-788. 1995
  • Seizure threshold in electroconvulsive therapy: I. Initial seizure threshold..  37:713-720. 1995
  • Clozapine decreases smoking in patients with chronic schizophrenia..  37:550-552. 1995
  • Influence of L-triiodothyronine on memory following repeated electroconvulsive shock in rats: implications for human electroconvulsive therapy..  37:198-201. 1995
  • Do anticonvulsants hinder clozapine treatment?.  37:132-133. 1995
  • Age dependent change of ventricular measures in schizophrenia: Cross-sectional analysis.  35:704-705. 1994
  • Fetal brain development of twins assessedIn utero by ultrasound.  35:623-623. 1994
  • Longitudinal classification in schizophrenia: The relationship between kraepelinian and deficit syndrome subtypologies.  35:695-695. 1994
  • Neuroleptic effects on CPT and eye tracking in schizophrenia.  35:674-674. 1994
  • Working memory dysfunction in Kraepelinian schizophrenics.  35:660-660. 1994
  • A pilot study of a structured interview addressing sexual function in men with schizophrenia..  35:32-35. 1994
  • The effects of ECT stimulus dose and electrode placement on the ictal electroencephalogram: an intraindividual crossover study..  34:759-767. 1993
  • Convulsive threshold differences in right unilateral and bilateral ECT..  34:606-611. 1993
  • Asymmetry of rCBF in schizophrenia: relationship to AP-gradient and duration of illness..  33:806-814. 1993
  • Cerebrospinal fluid monoamine metabolites in fluoxetine-treated patients with major depression and in healthy volunteers..  33:636-641. 1993
  • Depersonalization after marijuana smoking..  33:431-441. 1993
  • The dexamethasone suppression test and quantitative cerebral anatomy in depression..  33:442-449. 1993
  • Spectral and topographic analysis of EEG in schizophrenic patients..  33:284-290. 1993
  • Preliminary studies of 6 beta-hydroxydexamethasone and its importance in the DST..  32:825-833. 1992
  • Changes in middle cerebral artery velocity after marijuana..  32:164-169. 1992
  • Genetic animal models of depression and ethanol preference provide support for cholinergic and serotonergic involvement in depression and alcoholism..  31:919-936. 1992
  • Changes in cerebral blood velocity after intravenous diazepam..  31:690-697. 1992
  • Subcortical brain anatomy in anorexia and bulimia..  31:735-738. 1992
  • EEG evidence of more "intense" seizure activity with bilateral ECT..  31:617-621. 1992
  • Magnetic resonance findings in patients with early-onset Alzheimer's disease..  29:799-810. 1991
  • Platelet [3H]-imipramine binding and leukoencephalopathy in geriatric depression..  29:665-670. 1991
  • MRI of corpus callosum and septum pellucidum in depression..  29:300-301. 1991
  • Cardiovascular response to unilateral electroconvulsive therapy..  28:758-766. 1990
  • Comparison of urinary-free cortisol in depressed and nondepressed patients with malignancy..  28:522-525. 1990
  • Cerebral white matter disease in late-onset paranoid psychosis..  28:266-274. 1990
  • A brain magnetic resonance imaging study of pituitary gland morphology in anorexia nervosa and bulimia..  28:110-116. 1990
  • Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist..  28:169-173. 1990
  • Nocturnal and early morning secretion of ACTH and cortisol in humans..  28:47-57. 1990
  • Adrenocortical sensitivity to low-dose ACTH administration in depressed patients..  27:930-933. 1990
  • Plasma dexamethasone concentrations and the dexamethasone suppression test..  27:159-173. 1990
  • Neuroanatomical changes and hypothalamo-pituitary-adrenal axis abnormalities..  26:729-732. 1989
  • The prevalence of periodic limb movements during sleep in men with erectile dysfunction..  26:541-544. 1989
  • The corticotropin-releasing hormone test in patients with posttraumatic stress disorder..  26:349-355. 1989
  • Abnormalities in the response of plasma arginine vasopressin during hypertonic saline infusion in patients with eating disorders..  26:73-86. 1989
  • Differential sensitivity to dexamethasone suppression in an animal model of the DST..  26:26-34. 1989
  • Reduced inhibitory effect of imipramine on radiolabeled serotonin uptake into platelets in geriatric depression..  25:687-691. 1989
  • Psychoses associated with propranolol withdrawal..  25:351-354. 1989
  • Depression in early-onset Alzheimer's disease: clinical and neuroendocrine correlates..  24:937-940. 1988
  • MRI scans in patients with tardive dyskinesia..  24:852-857. 1988
  • Urinary 6-hydroxymelatonin in menstruating women..  24:845-852. 1988
  • Leukoencephalopathy in elderly depressed patients referred for ECT..  24:143-161. 1988
  • Adrenocortical sensitivity to ACTH in humans..  24:105-108. 1988
  • Topographic maps of brain electrical activity--pitfalls and precautions..  23:628-636. 1988
  • Leukoencephalopathy in patients diagnosed as major depressive..  23:519-522. 1988
  • CSF corticotropin-releasing factor-like immunoactivity in chronic pain patients with and without major depression..  23:86-88. 1988
  • ECT instrumentation.  24:361. 1988
  • Effect of gamma interferon on the hypothalamic-pituitary-adrenal system..  22:1163-1166. 1987
  • Elevated hematocrit in patients with schizophrenia..  22:907-910. 1987
  • Organic affective disorder in a patient with congenital adrenal hyperplasia..  22:767-770. 1987
  • Augmentation of ECT seizures with caffeine..  22:637-649. 1987
  • Diagnostic utility of the dexamethasone suppression test..  22:618-628. 1987
  • Electroconvulsive therapy of depression in patients with white matter hyperintensity..  22:629-636. 1987
  • Response.  21:428. 1986
  • Response.  21:428-. 1986
  • Weight change and the dexamethasone suppression test..  20:1018-1022. 1985
  • What does the dexamethasone suppression test identify?.  20:957-964. 1985
  • Platelet alpha-2-adrenergic dysfunction in negative symptom schizophrenia: a preliminary study..  20:539-545. 1985
  • ECT-induced amnesia and postictal EEG suppression..  20:344-348. 1985
  • Prolactin response to morphine in depression..  20:287-292. 1985
  • The dexamethasone suppression test in borderline personality disorder..  19:1149-1153. 1984
  • The effect of dexamethasone on sleep: preliminary results in eleven patients..  19:771-775. 1984
  • Effects of single and repeated alcohol withdrawal on kindling..  19:525-537. 1984
  • Biological markers for endogenous depression in series and parallel..  19:3-11. 1984
  • The dexamethasone suppression test in repeated hospitalizations..  18:1497-1502. 1983
  • The effect of isocarboxazid on platelet MAO activity..  18:1075-1079. 1983
  • Depressive pseudodementia: a suggested diagnostic profile..  18:215-225. 1983
  • Autobiographical amnesia with ECT: an analysis of the roles of stimulus wave form, electrode placement, stimulus energy, and seizure length..  18:121-126. 1983
  • Sleep EEG, depression rating scales, and diagnosis..  17:1453-1458. 1982
  • The effects of ECT modifications on autobiographical and verbal memory..  17:919-924. 1982
  • Interference by carbamazepine with the dexamethasone suppression test..  17:611-620. 1982
  • Serial dexamethasone suppression tests among rapidly cycling bipolar patients..  17:455-462. 1982
  • EEG studies of sleep in the diagnosis of depression..  17:305-316. 1982
  • Speech pause time: a marker of psychomotor retardation among endogenous depressives..  16:851-859. 1981
  • Changes in serial dexamethasone suppression tests among unipolar depressive receiving electroconvulsive treatment..  16:551-560. 1981
  • Decrease in speech pause times with treatment of endogenous depression..  15:575-587. 1980
  • Normalization of dexamethasone suppression test: a laboratory index of recovery from endogenous depression..  15:449-458. 1980
  • ECT and seizure threshold: effects of stimulus wave form and electrode placement..  15:225-241. 1980
  • Severe premenstrual tension: delineation of the syndrome..  15:121-139. 1980
  • Catechol-O-methyltransferase activity and classification of depression..  14:937-942. 1979
  • Testosterone-attenuated stereotype and hyperactivity induced by beta-phenylethylamine in pargyline-pretreated rats..  13:455-463. 1978
  • 108. Hippocampal Subfield Volumes Relate to Unique Phenotypes of PTSD: International Analysis by the PGC-ENIGMA PTSD Working Group 2019
  • T126. Short- Vs Medium + Long-Chain Plasma Acylcarnitine in Phenotypes of Major Depression at Baseline and After Citalopram/Escitalopram Treatment 2019
  • F113. Hippocampal Connectivity Insulates High-Risk Adolescents From the Relationship Between Stress and Depressive Symptoms 2018
  • F179. Epigenetic Biomarkers in Women With Posttraumatic Stress Disorder After CRF1 Receptor Antagonist Treatment 2018
  • S80. Individual Differences of Spontaneous Angular Gyrus Brain Activity in Dissociating Moral Injury and Posttraumatic Stress Disorder 2018
  • T176. Controllability of Structural Brain Networks in Depressed Patients Receiving Repetitive Transcranial Magnetic Stimulation 2018
  • A Unique Dual Cortico-Striatal Action of a Beta-Arrestin Biased Dopamine D2 Receptor Ligand 2016
  • Cognitive Behavioral Strategies During Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder 2016
  • Epigenome-Wide Association of PTSD from Heterogeneous Cohorts with a Common Multi-Site Analysis Pipeline 2016
  • Genome-Wide Association of Neuroimaging Phenotypes in PTSD at Multiple Sites 2016
  • Neural Mechanisms of Emotion Regulation in Major Depression and Implications for Psychotherapy Effectiveness 2016
  • Re-evaluating the Electroconvulsive Therapy Stimulus: Train Duration 2016
  • Assessment of Myelin Compromise in Mild Traumatic Brain Injury with Quantitative Susceptibility Mapping 2015
  • Association of Obesity and Levels of Inflammatory Markers on Treatment Outcome with Adjunctive (6S)-5-methyl-5,6,7,8-tetrahydropteroyl-L-glutamic Acid (CH3-FH4) in MDD Patients Who are Inadequate Responders to SSRIs 2015
  • Autism Pay-per-view: Evidence for Differential Implicit Reward Value of Social and Nonsocial Stimuli in Children with Autism from an Econometric Choice Task 2015
  • Can We Use Brain Oscillations to Guide Treatment of MDD? 2015
  • Endurance of Neural Response to Rewards Predicts Post-Treatment Depression Severity 2015
  • Ictal EEG Correlates of Neurocognitive Outcome in Electroconvulsive Therapy and Magnetic Seizure Therapy 2015
  • Mesocorticolimbic Predictors of Responses to Psychotherapy in Major Depression 2015
  • Neural Mechanisms of Uncertainty Processing in Children with Autism Spectrum Disorders 2015
  • Positive Correlation Between Nightmares and Heart Rate Response to Loud Tones Supports Parasympathetic Dysfunction in Posttraumatic Stress Disorder 2015
  • Re-evaluating the Electroconvulsive Therapy Stimulus: Frequency and Directionality 2015
  • Restored WAVE1 Levels in a Model of NMDA Receptor Hypofunction Attenuates Working Memory Deficits 2015
  • The Late Positive Potential indicates Heightened Emotion Responses to Restricted Interests in Youth with Autism Spectrum Disorder 2015
  • Walking Corpse Syndrome Presenting With Catatonia: Case Report and Literature Review 2015
  • Fear Learning Circuitry in PTSD is Biased Toward Generalization of Conditioned Response 2014
  • Individualized Low Amplitude Seizure Therapy (iLAST) - Magnetic and Electric Approaches to Enhance Focality and Safety for Depression Treatment 2014
  • Neural Mechanisms and Psychophysiology of Emotion Regulation Impairments in Autism 2014
  • Prefrontal Cortex-amygdalar Circuit Dynamics Predict Stress Susceptibility 2014
  • The Impact of Eszopiclone Insomnia Treatment on Cognition in Schizophrenia: A Double-blind, Randomized, Placebo-controlled Trial 2014
  • Ultrabrief Right Unilateral ECT in Geriatric Depression: Antidepressant and Cognitive Outcomes 2014
  • A Multi-Site, Naturalistic Study of RTMS for Major Depressive Disorder 2013
  • A Pilot Study of Neuroplasticity Based Cognitive Remediation in Adolescents with Psychosis 2013
  • Adrenocortical Sensitivity to Endogenous ACTH in the CRH Test 2013
  • Change in Hippocampus Volume and Longitudinal Course of Late-Life Depression 2013
  • Diffusion Tensor Imaging of OEF/OIF Veterans with and without Exposure to Primary Blast Forces 2013
  • Lateralized Effects of Prefrontal Transcranial Magnetic Stimulation on Emotional Working Memory 2013
  • Lisdexamfetamine Dimesylate Augmentation Effects on Executive Function in Major Depressive Disorder Based on Level of Executive Function Impairment 2013
  • Network Analysis of Intrinsic Functional Organization of the Brain in Mild Traumatic Brain Injury 2013
  • Neural Response to Loss Is Associated with Rumination in Remitted Major Depression 2013
  • Phosphorylation of MeCP2 in Reward-Related Circuits is Required for Amphetamine-Induced Conditioned Place Preference in Mice 2013
  • Pilot Study of Sustained Oxytocin Treatment in Children and Adolescents with Autistic Disorder 2013
  • Pregnenolone Rescues Schizophrenia-Like Behavior in Dopamine Transporter Knockout Mice 2013
  • Rate Sensitive Immediate Feedback Inhibition of ACTH Secretionby Endogenous Cortisol in Human CRH Test 2013
  • Vulnerability or Consequence: Amygdala Volume Changes with PTSD in a Large Case-Controlled Veteran Group 2013
  • BDNF Gene Polymorphism (Val66Met) Predicts Amygdala and Hippocampus Activation in Children Diagnosed with Anxiety as Preschoolers 2012
  • Midbrain Modulation of Hippocampus Dependent Learning in Singaporeans at Ultra High Risk for the Development of Schizophrenia 2012
  • Neuroactive Steroids Enhance Activation of Emotion Regulation Brain Circuits 2012
  • Randomized, Double-Blind, Placebo Controlled, Parallel Group Exploratory Study of GSK239512 for Cognitive Impairment in Stable Schizophrenia Subjects on Background Antipsychotic Therapy 2012
  • Resting State Connectivity Between Amygdalar Subregions and the Prefrontal Cortex is Disrupted in PTSD 2012
  • A Test of Causal Hypotheses of Psychopathic Traits: Reduced Emotional Responsiveness or Anomalous Attentional Control? 2011
  • Amygdala Reactivity in Singaporeans at Ultra High Risk for the Development of Schizophrenia 2011
  • Associations between Purine Metabolites and Clinical Symptoms in Schizophrenia 2011
  • Clinical Predictors of White Matter Disruption in Chronic Mild Traumatic Brain Injury among Post-9/11 Veterans 2011
  • Genotypic Differences in Angiotensin Receptor Genes in Late-Life Depression 2011
  • Reduced Amygdala and Hippocampal Volumes Associated with PTSD in Recent Military Veterans from Iraq and Afghanistan 2011
  • Repetitive Transcranial Magnetic Stimulation (rTMS) of the Superior Frontal Gyrus Modulates Craving for Cigarettes 2011
  • Stress Vulnerability Moderates the Association between White Matter Lesions and Late-Life Depression 2011
  • Daily Left Prefrontal TMS for Major Depression: A Sham-Controlled Multi-Site Randomized Trial (NIH Optimization of TMS for Depression Study, OPT-TMS) 2010
  • Effect of Supplementary Motor Area Modulation on Motor Cortex Excitability in Obsessive-Compulsive Disorder: Relations to Clinical Improvement 2010
  • Generalized Enhancement of Episodic Memory by Prior Reward Experience 2010
  • Modulation Effect of Rumination Trait and Low Tryptophan on Default-Mode Network Connectivity 2010
  • Proof-of-Concept Randomized Controlled Trial with Pregnenolone in Mild Traumatic Brain Injury 2010
  • Regulatory Focus and Reward Sensitivity: Integrating Social-Cognitive and Affective Neuroscience Perspectives 2010
  • Reversal of Consolidated Behavioral Sensitization and Associated Neurochemical Changes by Local Infusion of PKC Zeta (zeta) Inhibitory Pseudosubstrate (ZIP) Peptide in Nucleus Accumbens Core 2010
  • Static and Dynamic Cognitive Deficits in Childhood Precede Adult Schizophrenia: A 30-Year Study 2010
  • Temporo-Parietal Junction Stimulation in the Treatment of Depersonalization Disorder 2010
  • Translational Development of Novel Pharmacotherapeutic Strategies for Psychostimulant Dependence 2010
  • Differentiation of Reward Dependent Behavior Circuitry from Reward Anticipation with fMRI-Guided TMS 2009
  • Frequency-Dependent Effects of rTMS on Neurogenesis, Synaptic Plasticity, and Behavior 2009
  • Frontal Cortex GABA and Glutamate-Glutamine Levels in Schizophrenia Measured with Magnetic Resonance Spectroscopy 2009
  • Analgesic efficacy of milnacipran in animal models of chronic pain 2008
  • Atypical antipsychotic drugs and diabetes mellitus in the USFDA adverse event reporting system (AERS) database in pediatric and adult patients 2008
  • Brain activation during decisions involving behavioral risk: Adolescents v. adults 2008
  • Cognitive and sedative effects of guanfacine extended release in children and adolescents aged 6 to 17 years with attention-deficit/hyperactivity disorder: Safety and sleep effects 2008
  • Discriminative tryptophan pathway in first-episode neuroleptic-naive patients with schizophrenia 2008
  • Functional neuroimaging of social and executive processes in individuals with autism 2008
  • High dose magnetic seizure therapy (HD-MST) increases mossy fiber sprouting but not cellular proliferation in the primate dentate gyrus 2008
  • L-serine predicts self-reported pain in female OEF/OIF veterans 2008
  • Metabolomics and lipidomics of neuropsychiatric disorders: Emerging data 2008
  • Randomized sham controlled trial of transcranial magnetic stimulation (TMS) to the supplementary motor area (SMA) for the treatment of medication resistant obsessive-compulsive disorder (OCD) 2008
  • Trauma-related distractors modulate neural systems for working memory in posttraumatic stress disorder 2008
  • fMRI-guided rTMS in the remediation of sleep deprivation-induced performance deficits ina working memory task 2008
  • Cerebrospinal fluid DHEA levels are elevated in Alzheimer's disease, related to neuropathological disease stage, and correlated with brain DHEA levels 2007
  • Cognitive improvement correlates with weight gain in schizophrenia subjects receiving quetiapine but not other antipsychotics: Data from the CATIE trial 2007
  • Effect of electroconvulsive shock and magnetic seizure on gene expression profiles in the prefrontal cortex of the rhesus monkey 2007
  • Effect of electroconvulsive shock and magnetic seizure on gene expression profiles in the prefrontal cortex of the rhesus monkey 2007
  • Frontiers in TMS technology development: Controllable pulse shape TMS (cTMS) and magnetic seizure therapy (MST) at 100 Hz 2007
  • Metabolomic mapping of schizophrenia and atypical antipsychotic effects 2007
  • Neural systems for executive and emotional processing are modulated by level of posttraumatic stress disorder symptoms in Iraq war veterans 2007
  • Neuroactive steroids are related to psychiatric symptoms in veterans returning from iraq and Afghanistan 2007
  • Proof-of-concept trial with the neurosterold pregnenolone targeting neurocognitive and negative symptoms in schizophrenia 2007
  • Neurosteroids as candidate modulators of pathophysiology in Alzheimer's disease and nicotine dependence 2006
  • The effects of olanzapine, quetiapine, and risperidone on neurocognitive function in first-episode psychosis: A double-blind, 52-week comparison 2006
  • Baseline neurocognitive assessment of 1364 patients with schizophrenia in the clinical antipsychotic trials for intervention effectiveness (CATIE) project 2005
  • Elevated plasma A beta(1-42) in geriatric depression 2005
  • Neuroactive steroid alterations in posterior cingulate and parietal cortex in subjects with schizophrenia and bipolar disorder: Potential gender specificity 2005
  • Neuroactive steroids and neurodegenerative disorders: Investigations in subjects with Alzheimer's and relevance to neuropathological disease stage 2005
  • Neuroactive steroids in schizophrenia, PTSD, and Alzheimer's disease: Relevance to pathophysiology and treatment 2005
  • Neuroactive steroids, mood stabilizers, and neuroplasticity: Alterations following lithium and changes in Bcl-2 knockout mice 2005
  • Cognitive enhancement in schizophrenia: Ending the therapeutic nihilism 2004
  • Effect of olanzapine versus placebo on the neuropsychological status of prodromal subjects 2004
  • Neuroactive steroids in schizophrenia: Relevance to symptoms and therapeutics 2004
  • Nicotinic receptor modulation of attention: An endophenotype for therapeutic drug development 2004
  • PET imaging of prefrontal dopamine D1 receptors in chronic ketamine human abusers: A model for schizophrenia 2004
  • The relationship of cognition changes and other symptoms following antipsychotic treatment 2004
  • Antipsychotic treatment effects on progression of brain pathomorphology in first episode schizophrenia 2003
  • Comorbidity and depression treatment. 2003
  • Improved attention is associated with reductions in frontal lobe lactate levels in first episode psychosis 2003
  • Neurocognitive effects of olanzapine and low-dose haloperidol: A two-year treatment study in first episode psychosis 2003
  • Olanzapine induced reductions in frontal lobe lactate levels correlate with treatment response in first episode psychosis 2003
  • Neurosteroids and pharmacological treatment strategies in schizophrenia, depression, and anxiety disorders 2002
  • Visuospatial working memory in schizotypal personality disorder 1997
  • Visuospatial working memory in schizotypal personality disorder 1996
  • PERFORMANCE ON TESTS SENSITIVE TO FRONTAL-LOBE DYSFUNCTION AND DEFICIT-LIKE SYMPTOMS IN SCHIZOTYPAL PERSONALITY-DISORDER 1993
  • TASKS FROM MONKEY CORTEX STUDIES AND SPECIFIC PREFRONTAL DYSFUNCTION IN SCHIZOPHRENIA 1993